Correlation of Magnetic Resonance Spectroscopy Changes in Hippocampal and Perihippocampal Regions and Neuro-Psychologic Evaluation with Various Clinical Factors Following Whole Brain Radiotherapy in Brain Metastasis

Thimmaiah Naveen¹, Uday Krishna AS¹,*, Vezokhoto Phesao¹, Pasha Tanvir¹ and V. Lokesh¹

¹Department of Radiation Oncology, Kidwai Memorial Institute of Oncology, Bangalore, India
*Corresponding author: Department of Radiation Oncology, Kidwai Memorial Institute of Oncology, Dr Marigowda Road, 560029, Bangalore, India. Tel: +91-8861029640 Email: udayabc82@gmail.com

Received 2019 August 06; Revised 2019 September 03; Accepted 2019 September 30.

Abstract

Objectives: To study the correlation of magnetic resonance spectroscopy (MRS) changes in hippocampal and perihippocampal regions and neuro-psychologic evaluation with various clinical factors following whole brain radiotherapy in brain metastasis.

Methods: A total of 33 patients with newly diagnosed brain metastasis, referred to our Department of Radiation Oncology were recruited after a prior informed written consent. All patients underwent baseline clinical/neurological evaluation, detailed MMSE examination, gadolinium enhanced MRI along with MRS (for ratio of Choline: NAA = CNI) from the bilateral hippocampal and perihippocampal areas. All patients then underwent WBRT by two opposing lateral portals on a linear accelerator to a dose of 30 gray in 10 fractions delivered over 2 weeks. Serial evaluations along with MRS and MMSE score were done at 1st, 3rd and 6 months after WBRT. The trends of CNI and MMSE scores at last follow-up were correlated with various clinical factors.

Results: Our cohort had 33 patients, predominantly women (M:F, 12:21) with a median age of 47 years, median KPS (Karnofsky performance status) of 80, mean RPA (recursive partitioning analysis) class 2, primary histology (lung, breast, GI, Gy, GU, MUO (metastasis of unknown origin): 10, 11, 2, 4, 4, 2). Median survival of the cohort was 4 months. At the end of 14 months of follow-up 30% of the patients were alive with a mean KPS of 70. Trend in the CNI values with time showed that, KPS (P = 0.079), RPA class (P = 0.079), primary diagnosis site (P = 0.049), number of brain metastasis (P = 0.045) showed statistical significance in terms of change in mean value of CNI value at last follow-up. Site of primary (lung/breast vs. others, P = 0.02) and number of metastasis (solitary/oligo vs. multiple, P = 0.02) showed significant correlation with decline in CNI. The KPS at presentation (< 70 or > 70, P = 0.04); RPA class (class II or higher, P = 0.04); Site of primary (lung/breast vs. others, P = 0.01), presence of extracranial disease (yes or no, P = 0.045), number of metastasis (solitary/oligo vs. multiple, P = 0.06), Size of the largest metastatic lesion (< or > 4 cm, P = 0.02) showed significant correlation with decline in MMSE at last follow-up.

Conclusions: Cognitive functioning after WBRT is influenced by a number of factors; patient related, systemic disease burden and local tumor load. Local disease control has significant impact on preservation of neurocognition. The trend in the CNI index and MMSE scores at last follow-up correlated with various factors and can be used as a guide to aid in patient selection for hippocampus-avoidance WBRT.

Keywords: Brain Metastasis, Magnetic Resonance Spectroscopy, MMSE, Neurocognition

1. Background

Whole brain radiotherapy (WBRT) is an integral component in the management of brain metastasis (BM) (1, 2). Several studies have shown that, central nervous system tumor control is a strong predictor of neurocognitive decline than WBRT itself. Progression of brain metastasis is a much greater cause of neurocognitive dysfunction than WBRT alone (3). Even in studies combining WBRT and radiosurgery, tumor control was found to correlate with neurocognitive stability (4, 5).

2. Objectives

Our study was performed to correlate the changes in magnetic resonance spectroscopy from the hippocampal and perihippocampal areas and mini mental state examination after WBRT with various patient related, disease...
related and local tumor related factors to identify the patient cohort who may benefit from hippocampal avoidance WBRT.

3. Methods

We enrolled 33 patients referred to department of radiotherapy for management of BM. After the initial clinical and neurological assessment of patients, they underwent volumetric magnetic resonance spectroscopy of the bilateral hippocampal and perihippocampal areas to measure the choline-NAA index (CNI) which indirectly estimates the anatomical integrity of the region. A CNI value of less 1 indicates that the level of N-acetyl aspartate, the neurotransmitter of normal brain is higher compared to choline which is a marker of cell proliferation and damage. The CNI values were taken in a volumetric manner from the bilateral hippocampal and perihippocampal areas. Figure 1 shows MR spectroscopy peaks and definition of CNI.

Mini mental state examination (MMSE) was evaluated for all the patients to assess their baseline neurocognitive function status. All the patients then underwent WBRT on linear accelerator to a dose of 30 Gy in 10 fractions. The MRS and MMSE along with clinical and neurological evaluation were performed at 1 month, 3 months, and 6 months post WBRT. The trend of these values were correlated with 13 clinical factors; patient related (5), systemic disease related (4) and local brain disease related factors (4).

The patient related factors were, age (< 50 or > 50 years), KPS at presentation (< 70 or > 70), RPA (class 2 or higher), duration between last therapy for primary diagnosis and diagnosis of BM (< 6 months or > 6 months) and presenting complaint of BM (with or without motor deficit/CN (cranial nerve) palsy). The primary disease related factors were site of primary (lung/breast vs. others), histology (adenoca vs. other), and modalities of therapy used for primary [with or without systemic long term chemotherapy (a chemotherapy schedule lasting for 6 months such as in breast cancer and lung cancer) with or without biological agents] and presence of extracranial disease (yes or no). The local disease related factors were site of BM (supra or infratentorial), number of metastasis (solitary/oligo vs. multiple), size of the largest lesion (< or > 4 cm) and proximity to any perihippocampal region (< or > 2 cm).

Variation in the means of repeated measures of MRS and MMSE was tested by ANOVA and the variation of the mean was correlated with each prognostic factor by univariate and multivariate analysis.

4. Results

Our cohort had 33 patients, predominantly women (M:F, 12:21) with a median age of 47 years, distributed among all histological primary diagnoses (lung, breast, GI, Gy, GU, MUO: 10, 11, 2, 4, 4, 2) with median KPS of 70 and mean RPA class of 2. Table 1 shows the patient characteristics. Median survival of the cohort was 4 months. At the end of 14 months of follow-up, 30% of the patients were alive with a mean KPS of 70. Figure 2 shows the survival graph of the entire cohort.

Repeate measure ANOVA for the trend in the CNI values with time showed that, KPS (P = 0.079), RPA class (P = 0.079), primary diagnosis site (P = 0.049), number of brain metastasis (P = 0.045) showed statistical significance in terms of change in mean value of CNI value at last follow-up.

Univariate analysis of various factors for time to deterioration of CNI showed that; site of primary (lung/breast vs. others), P = 0.02 and number of metastasis (solitary/oligo vs. multiple), P = 0.02 showed significance. Figure 3 shows the trends in CNI and correlation with various clinical factors. Univariate analysis of various factors for time to deterioration of MMSE showed that; KPS at presentation (< 70 or > 70), P = 0.04; RPA class (class II or higher), P = 0.04; site of primary (lung/breast vs. others), P = 0.01, presence of extracranial disease (yes or no), P = 0.045, number of metastasis (solitary/oligo vs. multiple), P = 0.06, size of the largest lesion (< 4 cm or > 4 cm), showed (P = 0.02), statistical significance. Figure 4 shows the trends in MMSE and correlation with various clinical factors.

On multivariate analysis, factors with significant correlation to time to deterioration of CNI were duration between last therapy for primary diagnosis and diagnosis of BM (< 6 months or > 6 months, P = 0.012) and presenting complaint of BM (with or without motor deficit/CN palsy, P = 0.023). Factors with significant correlation to time to deterioration of MMSE were age (< 50 or > 50 years, P = 0.089) (this was reaching statistical significance due to small patient number), histology (adenoca vs. other, P = 0.023) and site of BM (supra or infratentorial, P = 0.038).

Factors such as duration of systemic long term chemotherapy prior to WBRT and proximity of the local disease to hippocampus did not show any significance on change in trend of CNI or MMSE values at the last follow-up or either multivariate or univariate analysis.

5. Discussion

Progression of brain metastasis is a much greater cause of neurocognitive dysfunction than WBRT. Compared to best supportive care, WBRT added higher progression free survival and better quality of life (6-8). The WBRT after surgical resection provides higher local and distant control rates without any difference in overall survival (9). WBRT is known to cause neurocognitive decline (10, 11) manifested usually as drop in mini mental state examination score and delayed recall as shown in a randomised controlled study.
Hippocampus, the seat for conversion and execution of long term to short term memory along with other areas in temporal and basi-frontal lobes are found to be the most common site to develop radiation induced damage \((13, 14)\). Hippocampal avoidance WBRT (HA-WBRT) has been the most widely accepted used method to mitigate the adverse neuro-psychologic effects of WBRT \((15-17)\). It is however essential to understand the basis of patient selection for HA-WBRT \((18, 19)\).

Our study was performed to assess the radiation induced changes in hippocampal and perihippocampal areas after WBRT and mini mental state examination; correlating it with various clinical factors (patient related, systemic disease factors and local disease factors) to identify the patient cohort who may actually benefit from hippocampal avoidance WBRT.

We found that factors such as KPS, RPA, location of primary and number of metastasis had significant impact on variation in the mean value of CNI at the last follow-up. Univariate analysis of various factors on trend of CNI over follow-up shows that patients with lung/breast primary and patients with multiple metastases showed a greater decline in CNI values. Univariate analysis of various factors on trend of MMSE over follow-up shows that patients with lower KPS, higher RPA, lung/breast primary, with extracranial disease, multiple metastasis and size of the largest lesion > 4 cm had a greater decline in MMSE values.

There was negative correlation of change in CNI at follow-up showing that patients older than 50 years, those patients who have received long duration chemotherapy and those patients with presence of BM in the supratentorial location showed a higher decline. There was positive correlation in patients who had longer time duration between the previous therapy and diagnosis of BM and those who did not have motor weakness/CN palsy at presentation of BM. Similarly, on MMSE, positive correlation with patients younger than 50 years, those patients who had non adenocarcinoma histology, infratentorial location of BM showed higher MMSE values at the last follow-up.
## Table 1. Patient Characteristics

| Variables                      | Findings               |
|--------------------------------|------------------------|
| **Age, y, mean ± SD**          | 46.6 ± 11.8            |
| 28 - 71                        |                        |
| **Gender, n**                  |                        |
| Male                           | 12                     |
| Female                         | 21                     |
| **KPS, mean ± SD**             | 67.2 ± 13              |
| 50 - 90                        |                        |
| **Primary tumor, n**           |                        |
| Lung                           | 10                     |
| Breast                         | 11                     |
| RCC                            | 4                      |
| MUO                            | 4                      |
| Gynaec.                        | 4                      |
| Cervix                         | 2                      |
| Ovary                          | 2                      |
| Rectum                         | 1                      |
| Esophagus                      | 1                      |
| **Brain metastasis, n**        |                        |
| 1                              | 12                     |
| 2 - 3                          | 7                      |
| > 3                            | 14                     |
| **Location of brain metastasis, n** |                |
| Supratentorial                 | 21                     |
| Infratentorial                 | 3                      |
| Both                           | 9                      |
| **Extracranial metastasis, n** |                        |
| **Prior treatment for primary, n** |                |
| Yes                            | 23                     |
| No                             | 10                     |
| **Patients diagnosed with brain metastasis at presentation, n** | |
| Lung                           | 9                      |
| MUO                            | 2                      |
| **Duration between primary treatment and diagnosis of brain metastasis** |       |
| < 6 months                     |                        |
| 6 - 12 months                  |                        |
| > 12 months                    |                        |
| Breast                         | 4                      |
| Lung                           | 9                      |
| RCC                            | 1                      |
| Gynaec.                        | 3                      |
| Rectum                         | -                      |
| Esophagus                      | -                      |
| **MRS**                        |                        |
| Pre-RT                         | 0.85                   |
| Post-RT                        |                        |
| 1st month                      | 0.83                   |
| 3rd month                      | 0.85                   |
| 6th month                      | 0.74                   |
| **MMSE, mean**                 |                        |
| Pre-RT                         | 25.7                   |
| Post-RT                        |                        |
| 1st month                      | 25.6                   |
| 3rd month                      | 24.7                   |
| 6th month                      | 25                     |

Hippocampal avoidance WBRT may be considered in patients with age less than 50 years, KPS of more than 70, RPA class II or higher, non-lung/breast histology, has not received long term systemic chemotherapy, time between
last therapy and primary disease is more than 6 months, no motor deficits at presentation of BM, solitary or oligo

BM, largest lesion less than 4 cm in size, located atleast 2 cm away from any perihippocampal region and BM located
in the infratentorial brain with controlled extracranial disease.

5.1. Conclusions

Our study shows that cognitive functioning after WBRT is influenced by a number of factors including patient related, systemic disease burden and local tumor load. The trend in the decline of CNI index and MMSE scores at each follow-up correlated with various clinical factors and can be used as a guide to aid in selecting patients for hippocampus-avoidance WBRT.

Footnotes

Authors' Contribution: Uday Krishna AS and Thimmapiah Naveen developed the original idea and the protocol, abstracted and analyzed data, wrote the manuscript, and is guarantor. Pasha Tanvir, V. Lokesh, and Vezokhoto Pheso contributed to the development of the protocol, abstracted data, and prepared the manuscript.

Conflict of Interests: Authors declare that they have no financial interests related to the material in the manuscript.

Ethical Approval: The study was approved by the Institutional review board and ethics committee at Kidwai Memorial Institute of Oncology

Funding/Support: There was no funding/support for this study

References

1. Chu FH, Hilarius BB. Value of radiation therapy in the management of intracranial metastases. Cancer. 1990;74(3):577-81. doi: 10.1002/1097-0424(199005)74:3<577::AID-CNCR2820740318>3.0.co;2-f.
2. DeAngelis LM, Mandell LR, Thaler HT, Kimmel DW, Galicich JH, Fuks Z, et al. The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery. 1989;24(6):798-805. doi: 10.1093/neuros/24.6.798.
3. Murray KJ, Scott C, Greenberg HM, Emani B, Seider M, Vora NL, et al. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: A report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys. 1997;39(3):571-4. doi: 10.1016/s0360-3016(97)00341-6. [PubMed: 9316314].
4. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA. 2006;295(21):2483-91. doi: 10.1001/jama.295.21.2483. [PubMed: 17057720].
5. Aoyama H, Tago M, Shirato H; Japanese Radiation Oncology Study Group Investigators. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: Secondary analysis of the [ROSG99-1 randomized clinical trial, JAMA Oncol. 2015;1(4):457-64. doi: 10.1001/jamaoncol.2015.0145. [PubMed: 2688254].
6. Gaspar L, Scott C, Roisman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745-51. doi: 10.1016/s0360-3016(96)00889-0. [PubMed: 9128946].
7. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70(2):510-4. doi: 10.1016/j.ijrobp.2007.06.074. [PubMed: 17931788].
8. Noordijk EM, Vecht CJ, Hazama-Reiche H, Padberg GW, Voormolen JH, Hoekstra H, et al. The choice of treatment of single brain metastases should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys. 1994;29(4):717-21. doi: 10.1016/0360-3016(94)90558-4. [PubMed: 8040016].
9. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA. 1998;280(7):1485-9. doi: 10.1001/jama.280.17.1485. [PubMed: 9809728].
10. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomized controlled trial. Lancet Oncol. 2009;10(11):1073-44. doi: 10.1016/s1470-2045(09)70263-3. [PubMed: 19801201].
11. Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(3):314-41. doi: 10.1200/JCO.2010.30.855. [PubMed: 21047706]. [PubMed Central: PMC3058272].
12. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):665-72. doi: 10.1016/S0140-6736(04)66250-8. [PubMed: 15158627].
13. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013;15(1):34-37. doi: 10.1093/neuono/nnt143. [PubMed: 23856241]. [PubMed Central: PMC3779047].
14. Gondi V, Tome WA, Mehta MP. Why avoid the hippocampus? A comprehensive review. Radiat Oncol. 2010;5(3):370-6. doi: 10.1186/1748-717X-5-370. [PubMed: 20970224]. [PubMed Central: PMC2997490].
15. Gondi V, Pugh SI, Tome WA, Caine C, Corn B, Kanner A, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 9033): A phase II multi-institutional trial. J Clin Oncol. 2014;32(34):3810-6. doi: 10.1200/JCO.2014.57.2909. [PubMed: 25349290]. [PubMed Central: PMC4219130].
16. Gondi V, Tome WA, Marsh J, Struck A, Ghia A, Turian JV, et al. Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: Safety profile for RTOG 0933. Radiat Oncol. 2010;5(3):327-31. doi: 10.1186/1748-717X-5-327. [PubMed: 20992503]. [PubMed Central: PMC2988132].
17. Gondi V, Tolakanahalli R, Mehta MP, Tewatia D, Rowley H, Kuo JS, et al. Hippocampal-sparing whole-brain radiotherapy: A "how-to" technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2010;78(4):1244-52. doi: 10.1016/j.ijrobp.2010.01.039. [PubMed: 20598457]. [PubMed Central: PMC2956309].
18. Gondi V, Mehta MP. Novel insights into the management of brain metastases. Curr Opin Neurol. 2010;23(6):556-62. doi: 10.1097/WCO.0b013e32833f8cb5. [PubMed: 20859206].
19. Pospisil P, Kazda T, Bulik M, Dobiaskova M, Burkon P, Hynkova L, et al. Hippocampal proton MR spectroscopy as a novel approach in the assessment of radiation injury and the correlation to neurocognitive function impairment: Initial experiences. Radiat Oncol. 2015;10(21). doi: 10.1186/s13014-015-0518-1. [PubMed: 26474857]. [PubMed Central: PMC4609038].